Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29154228 | 0.88 | — | — | |
| SCHEMBL9052051 | 0.76 | — | — | |
| SCHEMBL30103385 | 0.74 | CYP2C19 (0.35) | CYP2C19MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL320082 | 0.74 | CYP4F2 (0.35) | CD274HCAR2CYP2C19CYP4F2CYP4A11 | |
| SCHEMBL5802971 | 0.71 | HCAR2 (0.31) | HCAR2 | |
| SCHEMBL17675657 | 0.71 | EPHX1 (0.38) | HCAR2 | |
| SCHEMBL20031997 | 0.70 | EPHX1 (0.37) | HCAR2 | |
| SCHEMBL20032245 | 0.70 | EPHX1 (0.37) | HCAR2 | |
| SCHEMBL5683395 | 0.70 | EPHX1 (0.37) | HCAR2 | |
| SCHEMBL20031998 | 0.70 | EPHX1 (0.37) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083897-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. | 2024-03-14 | — | — | US | disclosed |
| EP-4281182-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | Hibercell, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2022159746-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022066917-A1 | 3-(6-AMINOPYRIDIN-3-YL)BENZAMIDE DERIVATIVES AS RIPK2 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-31 | — | — | WO | disclosed |
| US-7135564-B1 | Reusable solid support for oligonucleotide synthesis | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 2006-11-14 | — | — | US | disclosed |
| US-20060008813-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | ERITJA RAMON | 2006-01-12 | — | — | US | disclosed |
| EP-1228243-A4 | COMPOSITIONS AND METHODS OF SYNTHESIS AND USE OF NOVEL NUCLEIC ACID STRUCTURES | CYGENE INC (US) | 2005-07-20 | — | — | EP | disclosed |
| US-6831072-B2 | Such as 8-amino-2'deoxyadenosine by treating 8-azido-2'deoxyadenosine with aqueous solution of methylamine or dimethylamine; for targeting nucleic acids without amplification and less use of enzymes | CYGENE, INC. | 2004-12-14 | — | — | US | disclosed |
| EP-0877751-B1 | LINKER ARM FOR SOLID SUPPORT OLIGONUCLEOTIDE SYNTHESIS AND PROCESS FOR PRODUCTION THEREOF | UNIV TECHNOLOGIES INT (CA) | 2003-10-15 | — | — | EP | disclosed |
| US-20030135040-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | CYGENE, INC. | 2003-07-17 | — | — | US | disclosed |
| WO-2001032924-A1 | COMPOSITIONS AND METHODS OF SYNTHESIS AND USE OF NOVEL NUCLEIC ACID STRUCTURES | CYGENE, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
| EP-1091972-A1 | REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 2001-04-18 | — | — | EP | disclosed |
| US-6043353-A | FOR SOLID PHASE SYNTHESIS | UNIVERSITY TECHNOLOGIES INTERNATIONAL, INC. (CA) | 2000-03-28 | — | — | US | disclosed |
| US-6015895-A | REACTING A LINKER COMPOUND WITH A HYDROXY GROUP OF A NUCLEOSIDE AND A SOLID SUPPORT CAPABLE OF ESTERIFICATION; LINKER IS STABILE AGAINST SPONTANEOUS HYDROLYSIS AND EASILY CLEAVED WHEN NECESSARY | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 2000-01-18 | — | — | US | disclosed |
| WO-2000001711-A1 | REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 2000-01-13 | — | — | WO | disclosed |
| EP-0877751-A1 | LINKER ARM FOR SOLID SUPPORT OLIGONUCLEOTIDE SYNTHESIS AND PROCESS FOR PRODUCTION THEREOF | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 1998-11-18 | — | — | EP | disclosed |
| EP-0876390-A1 | REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS, PROCESS FOR PRODUCTION THEREOF AND PROCESS FOR USE THEREOF | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997023497-A1 | LINKER ARM FOR SOLID SUPPORT OLIGONUCLEOTIDE SYNTHESIS AND PROCESS FOR PRODUCTION THEREOF | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997023496-A1 | REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS, PROCESS FOR PRODUCTION THEREOF AND PROCESS FOR USE THEREOF | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 1997-07-03 | — | — | WO | disclosed |
| US-5112962-A | Oxalyl derivative provides quick release of product using mild conditions | NORTHWESTERN UNIVERSITY (US) | 1992-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083897-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | CD274 4868/4885HCAR2 2857/4885CYP2C19 4766/4885 |
| US-20030135040-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | ADAR, NSUN2, RNGTT | CD274 4885/4885HCAR2 4221/4885CYP2C19 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.